Stryker unveils Mako Total Knee 2.0 at the AAOS 2023 Annual Meeting

Next advancement of Mako SmartRobotics™ delivers on its clinical history and technology as total Mako procedures surpass 1 million worldwide

MAHWAH, N.J., USA – Stryker announced today the launch of Mako Total Knee 2.0, the next chapter in Mako SmartRobotics™, at the AAOS 2023 Annual Meeting in Las Vegas. Informed by over 500,000 Mako Total Knee procedures, Mako Total Knee 2.0 is designed to deliver the same, trusted outcomes surgeons expect from Mako with a new, elevated user experience.

Mako Total Knee 2.0 introduces a new intuitive design, customizable workflow and other key features, including an innovative digital tensioner that allows surgeons to assess the stability of the knee intraoperatively during a total knee arthroplasty (TKA) without the need for additional instrumentation. Mako Total Knee 2.0 is built on the legacy of Mako SmartRobotics™ and its three key components – 3D CT-based planning, AccuStop™ haptic technology and Insightful Data Analytics, which have shown better outcomes for total knee, total hip and partial knee patients, compared to manual surgery.1,2,3

“Mako Total Knee 2.0 combines our cutting edge Mako Technology with our clinically proven Triathlon implants to help surgeons deliver enhanced patient outcomes,” said Don Payerle, president of Stryker’s Joint Replacement division. “Over the last six years, we’ve gathered key feedback from our customers and incorporated those findings into the development of Mako Total Knee 2.0 – reflecting our ongoing commitment to our customers and their patients.”

Today, there are Mako Systems installed across 35 countries, and more than 1 million Mako procedures have been performed worldwide.

“Stryker’s recent 1 million procedure milestone is an unprecedented achievement in orthopaedic robotics and a testament to the overwhelming global adoption and patient impact of Mako SmartRobotics,” said Payerle. “We look forward to continuing to help so many patients get back to the activities they love.”

With over 3,000 cases to date, Mako Total Knee 2.0 began limited release in August 2022, and will continue to roll out in a phased approach in 2023, beginning in the United States and following with global launch activities in select markets.

AAOS 2023 attendees can visit Stryker’s booth (#4243) to learn more about Mako Total Knee 2.0. Stryker will hold live demonstrations, exhibitions and a symposium throughout the 2023 Annual Meeting. For more information, please visit —

Those living with joint pain are encouraged to speak with their healthcare professional about available treatment plans. As a provider, surgeons can help patients get educated on options that may help prevent further pain and complications. To learn more about joint health treatment options for patients, please visit

All surgery carries risk. Surgeons must rely on their own professional clinical judgment when deciding whether to utilize a particular technology when treating a patient in their own practice. Stryker does not dispense medical advice and recommends that surgeons be trained in the use of any technology before using it in surgery. Not all patients will have the same postoperative recovery and activity level. Individual results vary.

About Stryker
Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at

Media contact
Stryker, Joint Replacement
Niamh Grano
Sr. Communications Manager

1. Illgen, R, Bukowski, B, Abiola, R, Anderson, P, Chughtai, M, Khlopas, A, Mont, M. Robotic assisted total hip arthroplasty: Outcomes at minimum two year follow up. Surgical Technology International. 2017 July 25; 30:365-372.

2. Kayani B, Konan S, Tahmassebi J, Pietrzak JRT, Haddad FS. Robotic-arm assisted total knee arthroplasty is associated with improved early functional recovery and reduced time to hospital discharge compared with conventional jig-based total knee arthroplasty: a prospective cohort study. The Bone and Joint Journal. 2018;100-B:930-7.

3. Burger JA, Kleeblad LJ, Laas N, Pearle AD. Mid-term survivorship and patient-reported outcomes of robotic-arm assisted partial knee arthroplasty. Bone Joint J. 2020;102-B(1):108-116.

About Peter Coffaro 506 Articles
Peter Coffaro is a growth-driven and strategic executive with over 25 years of progressive management success in the medical device industry. With a proven track record and recognized expertise, Peter has established himself as one of the top influencers in medical sales, as acknowledged by prestigious publications such as the World Journal of Orthopedics, Exponential Healthtech, and Throughout his career, Peter has accumulated 10 years of combined sales management experience, excelling in various roles including Director, General Manager, Distributor, and Vice President. He has worked for industry-leading orthopedic companies such as Zimmer, DePuy, and Stryker, solidifying his deep knowledge and network within the field. Peter’s passion for innovation and emerging technologies led him to found OrthoFeed, an award-winning blog covering digital orthopedic news and emerging medical technologies. Through this platform, he stays at the forefront of the industry and contributes to the dissemination of valuable insights. Peter is a three-time Hall of Fame award winner at Johnson and Johnson, demonstrating his exceptional contributions and impact on the organization. His expertise extends to areas such as organizational development, business development, sales management, digital marketing, and professional education. Peter earned a B.S. degree in Biology and Chemistry from Northern Illinois University, further complementing his comprehensive understanding of the medical field. With his wealth of experience, strategic mindset, and dedication to advancing healthcare, Peter Coffaro is a valuable asset and leader in the medical device industry.

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.